Organic compounds -- part of the class 532-570 series – Organic compounds – Sulfur containing
Patent
1986-01-22
1990-03-06
Robinson, Douglas W.
Organic compounds -- part of the class 532-570 series
Organic compounds
Sulfur containing
568 34, 568374, C07C14700, C07C 49105
Patent
active
049067850
ABSTRACT:
26,26,26-Trifluoro-1.alpha.,25-dihydroxy-cholecalciferol, and the 25R or 25S epimer thereof, are described, as well as processes and intermediates utilized to prepare the same, as well as pharmaceutical compositions containing the same. 26,26,26-trifluoro 1.alpha.,25-dihydroxycholecalciferol and the 25R or 25S epimer thereof are useful agents in the treatment of disease states such as osteoporosis, osteodystrophy and leukemia.
REFERENCES:
patent: 4229358 (1980-10-01), DeLuca et al.
patent: 4391802 (1983-07-01), Suda et al.
Kobayashi et al., Tetrahedron, vol. 22, No. 43, pp. 4309-4312, 1981.
Proceedings of the Fifth Workshop on Vitamin D, 1982, pp. 1079-1084.
Dukoh, S. et al., The Ovary: A Target Organ for 1,25-dihydroxyvitamin D.sub.3. Endocrinology 112: 200-206, 1983.
Murao, S., "Control of Macrophage Cell Differentiation in Human Promyelocytic HL-60 Leukemia Cells by 1,25-dihydroxyvitamin D.sub.3 and phorbol-12-myristate-13-acetate", Cancer Res., 43 (8): 4989-4996, 1983.
Reitsma, P. et al., Vitamin D.sub.3 Regulates c-myc Oncogene Expression in HL-60 Leukemic Cells, J. Cell Biol., 97 (5): 347a, 1983.
Rigby, W. F. C. et al., 1,25-dihydroxyvitamin D.sub.3 Induces Granulocytic Differentiation and Myeloid Specific Antigens in the HL-60 Promyelocytic Leukemia Cell Line, Blood, 62 (5): 153a, 1983.
Olsson, I., and Lund, U., Induction of Differentiation of the Human Histiocytic Lymphoma Cell Line U937 by 1.alpha.,25-dihydroxycholecalciferol, Cancer Res., 43 (12) 5862-5867, 1983.
Eisman, J. A. et al., 1,25-dihydroxyvitamin-D Receptor in Breast Cancer Cells, Lancet, Dec. 22/29: 1335-1336, 1979.
Frampton, R. J. et al., Presence of 1,25-dihydroxyvitamin D.sub.3 Receptors in Established Human Cancer Cell Lines in Culture, Cancer Res., 42: 1116-1119, 1982.
Colston, K. et al., 1,25-dihydroxyvitamin D.sub.3 Receptors in Human Epithelial Cancer Cell Lines, Cancer Res., 42:856-859, 1982.
Sher, E. et al., Whole Cell Uptake and Nuclear Localization of 1,25-dihydroxycholecalciferol by Breast Cancer Cells (T47D) in Culture, Biochem J., 200:315-320, 1981.
Frampton, R. J. et al., Inhibition of Human Cancer Cell Growth by 1,25-dihydroxyvitamin D.sub.3 Metabolites, Cancer Res., 43:4443,4447, 1983.
Shiina, Y. et al., Biological Activity of 24,24-difluoro-1.alpha.,25-dihydroxyvitamin D.sub.3 and 1.alpha.,25-dihydroxyvitamin D.sub.3 -26,23-lactone in Inducing Differentiation of Human Myeloid Leukemia Cells, Arch. Biochem. Biophys., 220: 90-94, 1983.
Abe, E. et al., Differentiation of Mouse Myeloid Leukemia Cells Induce by 1.alpha., 25-dihydroxyvitamin D.sub.3, Proc. Natl. Acad. Sci U.S.A., 78: 4990-4994, 1981.
McCarthy, D., 1.alpha.,25-dihydroxyvitamin D.sub.3 Causes Granulocytes from patients with Chronic Granulocytic Leukemia to Differentiate into Monocytes-macrophages: This Effect is Mediated by a Protein Receptor, Exp. Hematol., 11 (Supp. 14): 200, 1983.
Honma, Y. et al., 1.alpha.,25-dihydroxyvitamin D.sub.3 and 1.alpha.-hydroxy Vitamin D.sub.3 Prolong Survival Time of Mice Inoculated with Myeloid Leukemia Cells, Proc. Natl. Acad. Sci. U.S.A., 80:201-204, 1083.
Sato, T. et al., Antitumor Effect of 1.alpha.-hydroxyvitamin D.sub.3, Tohoku J. Exp. Med., 138: 445-446, 1982.
McCarthy, D. M. et al., A Role for 1,25-dihydroxyvitamin D.sub.3 in Control of Bone Marrow-collagen Deposition?, Lancet, Jan. 14: 78-80, 1984.
Koeffler et al., "Induction of Macrophage Differentiation of Human Normal and Leukemic Myeloid Stem Cells by 1,25-Dihydroxyvitamin D.sub.3 and Its Fluorinated Analogues", Cancer Research, 44, 5624-5628, Dec. 1984.
Baggiolini Enrico G.
Pizzolato Giacomo
Truitt Gary A.
Uskovic Milan R.
Boxer Matthew
Gould George M.
Hoffmann-La Roche Inc.
Leon Bernard S.
Lipovsky Joseph A.
LandOfFree
Novel trifluorinated vitamin D3 intermediates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel trifluorinated vitamin D3 intermediates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel trifluorinated vitamin D3 intermediates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-48623